Phospho-Tau Bar Code: Analysis of Phosphoisotypes of Tau and Its Application to Tauopathy
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Tau is a microtubule-associated protein which regulates the assembly and stability of microtubules in the axons of neurons. Tau is also a major component of neurofibrillary tangles (NFTs), a pathological hallmark in Alzheimer’s disease (AD). A characteristic of AD tau is hyperphosphorylation with more than 40 phosphorylation sites. Aggregates of hyperphosphorylated tau are also found in other neurodegenerative diseases which are collectively called tauopathies. Although a large number of studies have been performed on the phosphorylation of AD tau, it is not known if there is disease-specific phosphorylation among tauopathies. This is due to the lack of a proper method for analyzing tau phosphorylation in vivo. Most previous phosphorylation studies were conducted using a range of phosphorylation site-specific antibodies. These studies describe relative changes of different phosphorylation sites, however, it is hard to estimate total, absolute and collective changes in phosphorylation. To overcome these problems, we have recently applied the Phos-Tag technique to the analysis of tau phosphorylation in vitro and in vivo. This method separates tau into many bands during SDS-PAGE depending on its phosphorylation states, creating a bar code appearance. We propose calling this banding pattern of tau the “phospho-tau bar code”. In this review article, we describe what is newly discovered regarding tau phosphorylation through the use of the Phos-Tag. We would like to propose its use for the postmortem diagnosis of tauopathy which is presently done by immunostaining diseased brains with anti-phospho-antibodies. While Phos-tag SDS-PAGE, like other biochemical assays, will lose morphological information, it could provide other types of valuable information such as disease-specific phosphorylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498 · cited 2×
“…Frontotemporal dementia with Parkinsonism linked to Chromosome 17 (FTDP-17), a tauopathy, is caused by the mutation of the tau gene MAPT indicates that tau may be a causative factor for other tauopathies in addition to FTDP17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundGoedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“These diseases are collectively called tauopathies (Lee et al., 2001).”
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 4×
“Tau is a microtubule (MT)-associated protein (MAP) predominantly expressed in the axons of neurons (Dehmelt and Halpain, 2005; Iqbal et al., 2016; Wang and Mandelkow, 2016).”
BackgroundInfluentialTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 3×
“Since each tauopathy differs in the affected regions and aggregated structures (Ballatore et al., 2007; Spillantini and Goedert, 2013; Wang et al., 2013; Arendt et al., 2016), the immunohistochemistry involving morphological information can serve as diagnosis.”
BackgroundDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“However, it has recently been shown that a small amount of tau is present in dendrites and dendritic spines (Ittner et al., 2010).”
BackgroundMutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474 · cited 1×
“…Frontotemporal dementia with Parkinsonism linked to Chromosome 17 (FTDP-17), a tauopathy, is caused by the mutation of the tau gene MAPT indicates that tau may be a causative factor for other tauopathies in addition to FTDP17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundTau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · cited 1×
“…Frontotemporal dementia with Parkinsonism linked to Chromosome 17 (FTDP-17), a tauopathy, is caused by the mutation of the tau gene MAPT indicates that tau may be a causative factor for other tauopathies in addition to FTDP17 (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 1998).”
BackgroundTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies
Sanders, D. W., Kaufman, S. K., DeVos, S. L., Sharma, A. M., Mirbaha, H., Li, A., Barker, S. J., Foley, A. C., Thorpe, J. R., Serpell, L. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.04.047 · Cited by 986
The MAP1 family of microtubule-associated proteins.
Dehmelt (2004) · Genome biology · doi:10.1186/gb-2004-6-1-204 · Cited by 972
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 3×
“Those (S/T)P sites are targeted by proline-directed protein kinases (PDPKs) such as MAPK (ERK, JNK, and p38 SAPK), GSK3β, Cdk5-p35/p25, and Dyrk1A (Chauhan et al., 2005; Ryoo et al., 2007; Hanger et al., 2009).”
BackgroundPhosphorylation affects the ability of tau protein to promote microtubule assembly.
Lindwall, G., & Cole, R. D. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42989-9 · Cited by 901 · cited 2×
“A number of phosphorylation sites have been found to regulate MTbinding and -assembly activity of tau and to be involved in development, morphogenesis, and the maintenance of axons in neurons (Lindwall and Cole, 1984; Dehmelt and Halpain, 2005; Wang and Mandelkow, 2016).”
BackgroundTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · cited 4×
“Tau is a microtubule (MT)-associated protein (MAP) predominantly expressed in the axons of neurons (Dehmelt and Halpain, 2005; Iqbal et al., 2016; Wang and Mandelkow, 2016).”
BackgroundInfluentialThe prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
Lu, P.-J., Wulf, G., Zhou, X. Z., Davies, P., & Lu, K. P. (1999) · Nature · doi:10.1038/21650 · Cited by 721
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · cited 1×
“For example, the treatment of neurons with Aβ oligomers induces the transfer of tau to dendrites with enhanced phosphorylation at 12E8 sites (Ser262 and Ser356), which are mediated by MARK, SAD or p70S6K localized in dendrites and spines (Zempel et al., 2010).”
BackgroundDickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642 · cited 1×
“A role for the HSP90-CHIP complex is suggested in pathology of tauopathies via its recognition and selective degradation of phosphorylated tau (Dickey et al., 2007).”
BackgroundArendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Proline-directed and non-proline-directed phosphorylation of PHF-tau
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., & Ihara, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.823 · Cited by 557
Alzheimer's disease drug development pipeline: 2017
Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549 · cited 1×
“Several protein kinase inhibitors are in Phase II trials for AD in 2017 (Cummings et al., 2017).”
BackgroundHanger, D. P., Byers, H. L., Wray, S., Leung, K.-Y., Saxton, M. J., Seereeram, A., Reynolds, C. H., Ward, M. A., & Anderton, B. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703269200 · Cited by 455 · cited 2×
“Among them, more than 40 sites are reported to be phosphorylated (Figure 1; Chauhan et al., 2005; Hanger et al., 2007; Wang et al., 2013; Iqbal et al., 2016), and most reside in the Pro-rich region and C-terminal tail region flanking the MT-binding repeats (MTBs).”
BackgroundAntibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy
Kondo, A., Shahpasand, K., Mannix, R., Qiu, J., Moncaster, J., Chen, C.-H., Yao, Y., Lin, Y.-M., Driver, J. A., Sun, Y., et al. (2015) · Nature · doi:10.1038/nature14658 · Cited by 445
Global Hairpin Folding of Tau in Solution
Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H.-J., & Mandelkow, E. (2006) · Biochemistry · doi:10.1021/bi0521543 · Cited by 432 · cited 1×
“Nevertheless, tau adopts a “paperclip-like shape” conformation where the N-terminal and C-terminal domains fold to approach the repeat domain (Jeganathan et al., 2006).”
BackgroundNuclear Tau, a Key Player in Neuronal DNA Protection
Sultan, A., Nesslany, F., Violet, M., Bégard, S., Loyens, A., Talahari, S., Mansuroglu, Z., Marzin, D., Sergeant, N., Humez, S., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.199976 · Cited by 421 · cited 1×
“Tau is also found in the nucleus where it exists mainly in a dephosphorylated state (Loomis et al., 1990; Greenwood and Johnson, 1995; Sultan et al., 2011).”
BackgroundMicrotubule-associated Protein/Microtubule Affinity-regulating Kinase (p110mark)
Meyer, H. E., Mandelkow, E.-M., Drewes, G., Trinczek, B., Illenberger, S., Biernat, J., Schmitt-Ulms, G., & Mandelkow, E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7679 · Cited by 388 · cited 1×
“For example, Ser262 in KXGS motifs in the repeat domain is phosphorylated by MARK, PKA and CaMKII with different activation mechanisms (Drewes et al., 1995; Sironi et al., 1998; Ando et al., 2016).”
BackgroundJeganathan, S., Hascher, A., Chinnathambi, S., Biernat, J., Mandelkow, E.-M., & Mandelkow, E. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805300200 · Cited by 278 · cited 1×
“Phosphorylation at AT8 and PHF sites open the structure to move the N-terminal and C-terminal away respectively (Jeganathan et al., 2008).”
BackgroundSite-specific phosphorylation of tau inhibits amyloid-β toxicity in Alzheimer’s mice
Ittner, A., Chua, S. W., Bertz, J., Volkerling, A., van der Hoven, J., Gladbach, A., Przybyla, M., Bi, M., van Hummel, A., Stevens, C. H., et al. (2016) · Science · doi:10.1126/science.aah6205 · Cited by 263 · cited 1×
“It has been recently reported that the phosphorylation at Thr205 specifically inhibits amyloid beta (Aβ) toxicity; (Ittner et al., 2016).”
BackgroundIn vivo phosphorylation sites in fetal and adult rat tau
Watanabe, A., Hasegawa, M., Suzuki, M., Takio, K., Morishima-Kawashima, M., Titani, K., Arai, T., Kosik, K. S., & Ihara, Y. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74447-0 · Cited by 231
Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226 · cited 1×
“This tau is not phosphorylated, at least at AD sites such as AT8, PHF-1, and AT-180 (Maas et al., 2000; Pooler et al., 2012).”
BackgroundShahpasand, K., Uemura, I., Saito, T., Asano, T., Hata, K., Shibata, K., Toyoshima, Y., Hasegawa, M., & Hisanaga, S.-I. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5927-11.2012 · Cited by 206 · cited 2×
“For example, it has been shown that Cdk5-p35/p25 phosphorylates Ser202 and Thr205 at the AT8 site (Shahpasand et al., 2012), but they are not phosphorylated at the same time by Cdk5-p35/p25.”
BackgroundSelf-citationDynamic association of tau with neuronal membranes is regulated by phosphorylation
Pooler, A. M., Usardi, A., Evans, C. J., Philpott, K. L., Noble, W., & Hanger, D. P. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.01.005 · Cited by 148 · cited 3×
“This tau is not phosphorylated, at least at AD sites such as AT8, PHF-1, and AT-180 (Maas et al., 2000; Pooler et al., 2012).”
BackgroundAndo, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005917 · Cited by 105 · cited 1×
“For example, Ser262 in KXGS motifs in the repeat domain is phosphorylated by MARK, PKA and CaMKII with different activation mechanisms (Drewes et al., 1995; Sironi et al., 1998; Ando et al., 2016).”
BackgroundThe effects of dephosphorylation on the structure of the projections of neurofilament
Hisanaga, S., & Hirokawa, N. (1989) · The Journal of Neuroscience · doi:10.1523/jneurosci.09-03-00959.1989 · Cited by 90 · cited 1×
“Dephosphorylation of NF-H decreases its apparent molecular size to 140 kDa (Julien and Mushynski, 1982; Hisanaga and Hirokawa, 1989).”
BackgroundSelf-citationWada, Y., Ishiguro, K., Itoh, T. J., Uchida, T., Hotani, H., Saito, T., Kishimoto, T., & Hisanaga, S.-I. (1998) · Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a022174 · Cited by 58 · cited 3×
“In in vitro experiments using Cdk5-p25 as a protein kinase, we found that tau was phosphorylated mainly at Thr205, Ser235, and Ser404 sequentially from the C-terminal to N-terminal sites.”
BackgroundSelf-citation
Cited by
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Alquezar, C., Arya, S., & Kao, A. W. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.595532 · Cited by 367
Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359
“This may be important during physiological synaptic and axonal pruning and plasticity processes (2).”
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Chelko, S. P., Keceli, G., Carpi, A., Doti, N., Agrimi, J., Asimaki, A., Beti, C. B., Miyamoto, M., Amat-Codina, N., Bedja, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf0891 · Cited by 92
“Furthermore, in its active form (nonphosphorylated S9), GSK3 phosphorylates proline-rich serine/threonine (PP[S/T]xP) motifs and/or (S/T)xxxx(S/T) motifs on target substrates (where x is any amino acid) (92).”
Metadata
- Authors
- Kimura, T., Sharma, G., Ishiguro, K., & Hisanaga, S.-I.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-02-06
- Volume
- 12
- Pages
- 44-44
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2792694489
- Cited by
- 114
- References
- 34
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.